Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: A preliminary report

Table 1 Baseline characteristics of all patients

Baseline characteristics	Number of patients underwent patch testing n = 24 (%)
Gender
Male	13 (54.2)
Female	11 (45.8)
M:F	1:1.8
Age (yr)
Range	18-75
Mean ± SD	45.70 ± 16.29
18-30	4 (16.7)
31-50	12 (50)
51-70	6 (25)
> 70	2 (8.3)
Time interval (d) between drug intake and ACDRs
Range	7-45
Mean ± SD	22.54 ± 12.19
Implicated drugs
Phenytoin	14 (58.3)
Carbamazepine	9 (37.5)
Phenobarbitone	2 (8.3)
Lamotrigine	1 (4.7)
Phenytoin1 + Carbamazepine	1 (4.7)
Phenytoin1 + Phenobarbitone	1 (4.7)
Clinical spectrum of ACDRs
DRESS	18 (75)
SJS-TEN overlap	2 (8.3)
TEN	2 (8.3)
SJS	1 (4.2)
Lichenoid drug eruption	1 (4.2)
Time interval (mo) between complete recovery from ACDRs and Patch test
Range	1-24
Mean ± SD	9.62 ± 6.62

¹Also included in 14 patients with ACDRs from Phenytoin. ACDRs: Adverse cutaneous drug reactions; DRESS: Drug rash with eosinophilia with or without systemic involvement; SJS: Stevens-Johnsons syndrome; TEN: Toxic epidermal necrolysis.